Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study

Clinical Therapeutics

Volumn 28, Issue 5, 2006, Pages 745-754

  Gathe Jr , Joseph C ^a   Wood, Robin ^b   Sanne, Ian ^c   Dejesus, Edwin ^d   Dirk, Schürmann ^e   Gladysz, Andrzej ^f   Garris, Cindy ^g   Givens, Naomi ^h   Elston, Robert ^h   Yeo, Jane ^h  

^a Therapeutic Concepts   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Clinical HIV Research Unit Parktown   (South Africa)

^d ORLANDO IMMUNOLOGY CENTER   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g GLAXOSMITHKLINE   (United States)

^h Greenford   (United Kingdom)

Author keywords

fosamprenavir; HIV 1; long term antiretroviral therapy.; protease inhibitors; ritonavir; SOLO

Indexed keywords

AMPRENAVIR PHOSPHATE; PROTEINASE; RITONAVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VIRUS RNA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DEMOGRAPHY; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTATION; NAUSEA; PANCREATITIS; PHENOTYPE; RECURRENT DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ADULT; AGED; CARBAMATES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RITONAVIR; SULFONAMIDES; TIME;

EID: 33746783331     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.05.011     Document Type: Article

References (16)

1. Deeks S.G., Wrin T., Liegler T., et al. Virologic and immunologic consequences of discontinuing combination anti retroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 344 (2001) 472-480
2. Lawrence J., Mayers D.L., Hullsiek K.H., et al., 064 Study Team of the Terry Beim Community Programs for Clinical Research on AIDS. Structured treatment interruption in patients with multidrug-resistant human immunodef ciency virus. N Engl J Med. 349 (2003) 837-846
3. Mocroft A., Ledergerber B., Katlama C., et al., EuroSIDA Study Group. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 362 (2003) 22-29
4. Gandhi T., Wei W., Amin K., and Kazanjian P. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy. Gin Infect Dis. 42 (2006) 878-884
5. Valdez H., Chowdhry T.K., Asaad R., et al. Changing spectrum of mortality due to human immunodefciency virus: Analysis of 260 deaths during 1995-1999. Clin Infect Dis. 32 (2001) 1487-1493
6. San Francisco, Calif Abstract 505. Spaltenstein A., Baker C., Gray-Nunez Y., et al. Highly polar, water-soluble prodrugs of amprenavir: A new approach toward a more compact dosing regimen. Presented at: 7th Conference on Retroviruses and Opportunistic Infections (January 30-February 2, 2000)
7. San Francisco, Calif Abstract 916. Baker C.T., Chaturvedi P.R., Hale M.R., et al. Discovery of VX175/GW433908, a novel, water soluble prodrug of amprenavir. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (September 26-29, 1999)
8. Rodriguez-French A., Boghossian J., Gray G.E., et al. The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defc Syndr 35 (2004) 22-32
9. Gathe Jr. C., Ive P., Wood R., et al. SOLO: 48-Week efficacy and safety comparison of once-daily fosamprenavir/ ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18 (2004) 1529-1537
10. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 41 (1992) 1-19
11. Division of AIDS. Table for Grading Severity of Adult Adverse Experiences (1992), National Institute of Allergy and Infectious Diseases, Rockville, Md
12. Johnson V.A., Brun-Vezinet F., Clotet B., et al., International AI DS Society-USA Drug Resistance Mutations Group. Drug resistance mutations in HIV-1. Top HIV Med. 11 (2003) 215-221
13. Schurmann D., Elston R., Xu F., et al. Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations. AIDS 20 (2006) 138-140
14. MacManus S., Yates P.J., Elston R.C., et al. GW433908/ ritonavir once-daily in antiretroviral therapy-naive HIV infected subjects: Absence of protease resistance at 48 weeks. AIDS 18 (2004) 651-655
15. Available at. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-I-Infected Adults and Adolescents. Accessed May 5, 2006 (May 4, 2006). http://aidsinfo.nih.gov/Con_ten_tFiles/AduItandAdolescentsGF.pdf
16. Kempf D.J., King M.S., Bernstein B., et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 189 (2004) 51-60